Arcus casdatifan: two new trials recruiting, hepatic PK study and RCC gene expression pilot
Two casdatifan studies are recruiting, one comparing pharmacokinetics in hepatic impairment and one examining gene expression in refractory kidney cancer.
Arcus Biosciences has two casdatifan (AB521) trials actively recruiting this quarter.
- A Phase 1 pharmacokinetics study is recruiting to compare single dose pharmacokinetics of casdatifan between participants with moderate hepatic impairment and healthy matched control participants with normal hepatic function.1 The study started 2026-08-14 and enrolls 16 participants at a single site in San Antonio, Texas.1
- A Phase 1 pilot study sponsored by Vanderbilt-Ingram Cancer Center, with Arcus as collaborator, is recruiting patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies2 to study casdatifan's effect on tumor gene expression. The trial dosed patients orally once daily on days 1-28 of each 28-day cycle, with two permitted dose reductions to 50mg then 25mg for drug-related adverse events2, and started 2026-09-21 with 12 participants estimated.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.